Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	444.09	281.59	202.13	402.71	129.09
Depreciation & Amortization	81.31	82.36	49.64	3	3.28
Other Amortization	7.35	7.3	7.84	3.64	14.14
Loss (Gain) From Sale of Assets	1.53	0.61	0.13	-	-0.77
Asset Writedown & Restructuring Costs	-	2.5	-	-	0.58
Loss (Gain) From Sale of Investments	-10.93	-6.32	2.83	2.26	0.84
Stock-Based Compensation	43.39	36.62	24.4	20.82	17.2
Other Operating Activities	1.6	22.58	39.09	-136.72	-0.53
Change in Accounts Receivable	-74.25	-3.34	-83.94	6.76	-38.29
Change in Inventory	-67.38	-26.88	-17.48	7.37	-31.39
Change in Accounts Payable	46.99	-12.55	24.54	1.17	-41.21
Change in Other Net Operating Assets	5.36	4.1	-9.06	-11.56	2.52
Operating Cash Flow	479.06	388.57	240.11	299.44	55.45
Operating Cash Flow Growth	23.29%	61.83%	-19.81%	439.98%	-
Capital Expenditures	-10.7	-15.29	-4.81	-1.46	-2.5
Sale of Property, Plant & Equipment	-	-	26.01	-	1.08
Cash Acquisitions	-	-	-999.12	-	-
Investment in Securities	-252.03	-81.62	490.92	-404.83	79.78
Investing Cash Flow	-262.72	-96.91	-487.01	-406.29	78.35
Short-Term Debt Issued	-	-	370	-	-
Long-Term Debt Issued	-	-	702	784.88	-
Total Debt Issued	-	-	1,072	784.88	-
Short-Term Debt Repaid	-	-	-370	-	-
Long-Term Debt Repaid	-	-13.48	-77.45	-369.06	-19.56
Total Debt Repaid	-	-13.48	-447.45	-369.06	-19.56
Net Debt Issued (Repaid)	-	-13.48	624.55	415.81	-19.56
Issuance of Common Stock	31.14	7.88	14.05	12.54	63.39
Repurchase of Common Stock	-250	-402.38	-200	-350.06	-150.12
Other Financing Activities	-	-	-76.22	-0.42	-
Financing Cash Flow	-218.86	-407.99	362.37	77.87	-106.28
Net Cash Flow	-2.52	-116.33	115.48	-28.98	27.52
Free Cash Flow	468.37	373.28	235.3	297.98	52.95
Free Cash Flow Growth	25.47%	58.64%	-21.04%	462.76%	-
Free Cash Flow Margin	46.13%	45.01%	35.64%	67.22%	19.79%
Free Cash Flow Per Share	3.62	2.78	1.67	2.03	0.37
Cash Interest Paid	10.57	11.41	6.11	3.3	6.53
Cash Income Tax Paid	80.62	31.76	16.22	-0.38	0.18
Levered Free Cash Flow	395.43	274.74	146.42	197.82	3.92
Unlevered Free Cash Flow	399.38	279.16	149.17	198.88	2.52
Change in Working Capital	-89.28	-38.67	-85.95	3.74	-108.37

Updated Nov 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q